Metastatic colorectal cancer responsive to regorafenib for 2 years: a case report

Regorafenib is an oral multikinase inhibitor that has been demonstrated as clinically effective in patients with metastatic colorectal cancer in phase III studies. Although disease control was achieved in 40% ...

http://ift.tt/2wmLxWF